DermTech Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bret Christensen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Bret Christensen (52 yo)

less than a year

Permanencia

Mr. Bret Christensen serves as Chief Executive Officer, President and Director at DermTech, Inc. since May 2023. He serves as Director of Axena Health, Inc. Mr. Christensen had been Chief Commercial Office...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Sun	CFO, Treasurer & Secretary	4.1yrs	US$1.46m	0.42% $ 4.0m
Claudia Ibarra	Chief Operating Officer	4yrs	US$1.20m	0.25% $ 2.3m
Ray Akhavan	General Counsel	2.8yrs	US$1.20m	0.12% $ 1.2m
Bret Christensen	President	less than a year	sin datos	sin datos
William Zondler	Chief Information Officer	less than a year	sin datos	sin datos
Steve Kunszabo	Senior Director of Investor Relations	no data	sin datos	sin datos
Jennifer Eilemberg	Chief Compliance Officer	1.3yrs	sin datos	sin datos
Ray Bassi	Vice President of Sales	2.3yrs	sin datos	sin datos
Burkhard Jansen	Chief Medical Affairs Officer	6.8yrs	US$480.83k	sin datos
Daniel Visage	Senior Vice President of Payer Access	4.8yrs	sin datos	sin datos
Loren Clarke	Chief Medical Officer	2.3yrs	sin datos	sin datos
Steven Stone	Senior Vice President of Research & Development	1.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DMTK * se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bret Christensen	President	less than a year	sin datos	sin datos
Herman Rosenman	Independent Director	4.2yrs	US$239.85k	0.29% $ 2.8m
Kirk Malloy	Independent Director	1.3yrs	US$312.01k	0.013% $ 123.4k
Matthew Posard	Independent Chairman of the Board	7.3yrs	US$272.18k	0.36% $ 3.4m
Mark Capone	Independent Director	1.3yrs	US$312.43k	0.059% $ 556.2k
Cynthia Collins	Independent Director	4.2yrs	US$240.18k	0.21% $ 1.9m
Nathalie Keraudy	Independent Director	2yrs	US$217.05k	0.092% $ 867.6k

2.0yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de DMTK * no se considera experimentada (2 años de permanencia promedio), lo que sugiere una nueva junta directiva.

DermTech Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces Change of CEO

DermTech, Inc. Announces Board Committee Appointments

Chief Operating Officer recently sold Mex$292k worth of stock

Recent updates

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

DermTech, Inc. Announces Change of CEO

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

DermTech, Inc. Announces Board Committee Appointments

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Chief Operating Officer recently sold Mex$292k worth of stock

High number of new directors

Second quarter 2022 earnings released: US$0.99 loss per share (vs US$0.59 loss in 2Q 2021)

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

High number of new and inexperienced directors

Dermtech Announces New Board Appointment

High number of new and inexperienced directors

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech, Inc. announced delayed annual 10-K filing

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

DermTech, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

High number of new and inexperienced directors

DermTech, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new and inexperienced directors

President recently sold Mex$687k worth of stock

Chief Operating Officer recently sold Mex$1.3m worth of stock

High number of new and inexperienced directors

DermTech Unveils DermTech Stratum

Third quarter 2021 earnings released: US$0.68 loss per share (vs US$0.50 loss in 3Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$3.1m worth of stock

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.58 loss in 2Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$2.5m worth of stock

President recently sold Mex$7.6m worth of stock

Dermtech, Inc. Provides Earnings Results for the Second Quarter of 2021

DermTech, Inc. Provides No Financial Guidance for the Fiscal Year 2021

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad